NTLA
USDIntellia Therapeutics Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$8.200
Máximo
$8.445
Mínimo
$8.060
Volume
9.93M
Fundamentos da empresa
Capitalização de mercado
864.9M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
4.19M
Bolsa de valores
NGM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $54
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics with a Buy and lowers the price target from $74 to $54.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $10 Price Target
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics with a Neutral and maintains $10 price target.
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline,
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.